H.C. Wainwright Believes Voyager Therapeutics Inc (VYGR) Still Has Room to Grow


In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Voyager Therapeutics Inc (VYGR), with a price target of $26. The company’s shares closed yesterday at $26.75, close to its 52-week high of $27.58.

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 0.8% and a 43.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Autolus Therapeutics Plc.

Voyager Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $29.75, representing an 11.2% upside. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $27.17 million. In comparison, last year the company had a GAAP net loss of $19.93 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts